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A B S T R A C T
Modiﬁed Atkins diet (MAD) is a less restrictive variety of the classical ketogenic diet (KD), used for
treating patients with medically resistant epilepsy. There are only few reports comparing the two types
of diets in terms of seizure reduction and tolerability. We compared the effect of a MAD evaluated
prospectively on 33 consecutive children with medically resistant epilepsy, with a group of 50 patients,
previously treated with KD. Patients who had>50% seizure reduction were considered responders. After
3 months on the MAD, 17 patients (52%) were responders, including 14 (42%) who had >90% seizure
reduction. After 6months, 13 patients (39%) were responders. Seventeen patients (52%) remained on the
MAD at least 12monthswith excellent overall tolerance and compliance, including 9 patients (27%) who
were responders, 4 of them (12%) having >90% seizure reduction. Although there was a trend for higher
incidence of responders in the KD group, this failed to reach the level of signiﬁcance: after 6 months 39%
on MAD and 60% on KD were responders. However, this trend was not observed when the two groups
were adjusted for difference in age (patients in the MAD group were older than the KD group). In
conclusion, our experience suggests that the MAD is similarly effective as the KD in reducing seizure
frequency in children with medically resistant epilepsy.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Approximately 25% of all children with epilepsy do not respond
sufﬁciently to antiepileptic drugs (AEDs) and are considered
medically intractable. Classical ketogenic diet (KD), a low
carbohydrate, low-to-adequate protein and high fat diet, has been
applied to many of those children, especially over the last 2
decades in Europe.1–6 However, KD has been known and used for
nearly a century.7 KD results in >50% seizure reduction in at least
50% of the children. Approximately 10% will eventually become
completely seizure-free and even medicine-free.8
The modiﬁed Atkins diet (MAD) is a less restrictive alternative
ketogenic diet, based on the same principles as classical KD.9
TheMAD is a diet where carbohydrates are initially restricted to
10 g per day, but otherwise free intake of protein, fat and calories is
allowed, and high fat intake is encouraged.10 The MAD ratio of fat/
protein and carbohydrates is on average 1:1, while KD ratios are* Corresponding author at: Department of Paediatrics, Danish Epilepsy Centre,
Filadelﬁa, Dianalund, Denmark. Tel.: +45 58 27 10 68; fax: +45 58 27 14 71.
E-mail address: mamr@ﬁladelﬁa.dk (M.J. Miranda).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.11.010most often 3–4:1, yet both diets induce ketosis (average occidental
foods are 0.3:1). The MAD was developed in the US at the Johns
Hopkins hospital in early 2000s,11 based and inspired on the well-
known Atkins diet, widely used in the US for obesity management.
In the last 7 years, since the ﬁrst report appeared,11 11 reports
from 6 countries10–20 and 1 review9 have been published. Two of
the reports were on adults.13,18 A few of the previous publications
suggested that the MAD has an efﬁcacy close to the KD. However,
randomised studies comparing the efﬁcacy of MAD and KD have
not been performed yet. The MAD can be used as a diet of ﬁrst
choice in a childwith intractable epilepsy or as away of liberalizing
the classical KD treatment.9
In Denmark, treatment of severe and medically intractable
epilepsies is mostly centralized at The Danish Epilepsy Centre
where the majority of Danish patients (children and adults)
receiving KD are treated too. After the ﬁrst Danish experience with
a few patients treated with MAD,17 we standardized the MAD
protocol and began to offer MAD regularly to drug-resistant
patients in our Institution, in addition to classical KD. MAD has
been used since June 2007 as a standard treatment offered to a
great proportion of patients referred or considered candidates for
KD but where a liberalized type of diet was deemedmore suitable;vier Ltd. All rights reserved.
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exception of patientswith gastrostomy. This study summarizes the
Danish protocol for MAD, describes the ﬁrst 38 patients treated
since June 2007, the efﬁcacy in terms of seizure control,
compliance, side effects, as well as induction of ketosis, impact
on blood fat parameters (cholesterol and triglycerides), and the
global impression of change, as reported by the parents, based on
changes in attention, behaviour and sleep. Lastly, we compared the
efﬁcacy of MAD in these patients with the KD in 50 consecutive
children previously treated at our Institution.
2. Patients and methods
2.1. Patients
Fromthe1st June2007until the31stMarch2009(22months), 38
children, aged (at diet start) 1.1–15.6 years (mean 8.1 years) were
offered and accepted treatment with MAD, whilst in the same time
period 33 were started on KD, for their medically intractable
epilepsy. Children were referred to the ketogenic diet team at the
Danish Epilepsy Centre, either fromour own Centre or from another
paediatric neurology clinic in Denmark, for diet treatment of their
epilepsy. After a ﬁrst visit with one of the paediatric neurologists at
the KD team (MM), parents and doctor together decidedwhich diet,
MAD or classical KDwasmore suitable for their child and the family
(i.e. selection of candidates for MADwas made on individual basis).
Parentswere counselled on the advantages anddisadvantages of the
diets. Parents of the older children opted more often for the MAD,
because they also doubted their children would comply with the
stricter regimen of the KD. Parents of the younger childrenweighed
less the compliance issue (younger children only eat what they areTable 1
Patient characteristics (MAD).
Pt. nr./
gender
Epilepsy
onset Age (y)
Epilepsy type Etiology/syndrome
1/F 0.4 P/sG Lissencephaly
2/M 4 P/sG CSWS Perinatal stroke/CSWS
3/F 7 P/sG Band heterotopia
4/M 0.8 P/sG Congenital CMV
5/M 0.8 P/sG Stroke (arteria carotis malf.)
6/F 0.4 G (abs, GTC, my) Dravet Syndrome (S) spectrum (SC
7/M 0.5 G Myoclonic absences
8/M 8.6 G Idiopathic/unknown
9/F 0.6 Spasms MCD (cortical dysplasia bilateral)
10/F 0.5 G (abs, GTC, my) Dravet S (SCN1A+)
11/M 1 Spasms MCD (cortical dysplasia bilateral)
12/F 7.5 P/sG Cryptogenic Focal
13/F 2.4 P/sG CSWS Perinatal stroke/CSWS
14/M 2.8 P/sG CSWS Cryptogenic CSWS
15/F 0.4 P/sG MCD (CC hypoplasia)
16/F 0.08 P/sG Unknown
17/M 2.8 G MAE/LGS idiopat/cryptogenic
18/M 6.1 P/sG Encephalitis sequelae
19/F 2.5 P/sG Dravet S (SCN1A)
20/M 3.8 G Myoclonic absences
21/F 0.25 P MCD (cortical dysplasia bilateral)
22/M 2.1 P/sG MCD
23/F 8 P/sG Perinatal cerebral haemorrhage
24/M 0.4 G Dravet S (SCN1A+)
25/M 7 P/sG Frontal lobe epilepsy (cryptogenic)
26/F 0.3 P/sG Corpus callosum dysgenesis
27/F 0.25 G Dravet/GEFS+ (SCN1A+)
28/F 0.4 G Dravet S (SCN1A+)
29/M 0.8 Spasms Autism (cryptogenic)
30/M 0.3 P/sG Lissencephaly (LIS1+)
31/F 1.4 P MCD
32/F 3 P/G Frontal lobe epilepsy (cryptogenic)
33/F 0.4 G MAE
CC: corpus callosum; CMV: cytomegalovirus; CSWS: encephalopathy with continuous
epilepsy with febrile seizures plus; LGS: Lennox–Gastaut Syndrome; malf.: malformatio
Mo: months; my: myoclonia; P: partial epilepsy; sG: secondary generalised; and y: yegiven) and opted more often for the KD because the more robust
evidence for the efﬁcacy of this type of diet. Parents were also
advised that they could switch from one diet to the other in case of
side effects or lack of efﬁcacy.
All diet candidates had more than 1 seizure per week, and had
tried at least 3 AEDs without achieving acceptable seizure control.
Three (out of 38) changed their minds after the ﬁrst 2 outpatient
visits with doctor and dietician respectively, and never started
dietary treatment. Additionally 2 children were on the diet for less
than 1 month and were therefore excluded from the study. Thirty-
three children (15 males and 18 females) started the MAD, and
have been on the MAD between 2 and 22 months (mean 8.7
months) at time of analysis.
With respect to their epilepsy diagnosis, 23 had focal/multifocal
(symptomatic/cryptogenic) epilepsies, 6 Dravet Syndrome, 2
myoclonic absences and 2 myoclonic astatic epilepsy (MAE).
The interval between epilepsy onset and diet treatment was 7.3
years (15.5–1). Patients had tried amedian of 7 (13–3)medications
before the diet. Patient details are shown in Table 1.
2.2. Modiﬁed diet protocol
All patients referred to our Centre with medically intractable
epilepsy, and who are not considered surgery candidates or whose
parents chose not to pursue surgical treatment, are typically
offered diet treatment. During a ﬁrst consultation with paediatric
neurologist, diet treatment is discussed. Once decided to try MAD
following the considerations mentioned above, a second appoint-
ment is made with the nurse and the dietician. In the meantime,
blood samples are taken in order to rule out carnitine deﬁciency/
beta-oxidation defects. If no contraindication for the diet is found,Age MAD
(years) start
MAD duration:
months
AED
tried (n)
AED at start of MD
6.5 22 6 LEV, NTZ
9 11 8 0
15.4 2 5 CBZ
4.3 9 8 LEV, ZNS, PGB
5.8 10 12 VPA, PGB
N1A) 2.3 22 5 TPM, LEV
10.9 18 5 LTG
10.2 3 6 TPM, LEV
2.8 15 10 LEV
15.6 3 9 VPA, LTG, CZP, VNS
3.4 7 10 ZNS, CLB
13.4 4.5 4 LEV
8.3 2 5 LEV, STM
6 13 5 STM
12.5 13 6 0
9.3 8 13 LEV
7.9 13 9 TPM, CLB
12.8 10 CLB
9.4 10 11 STIR, CLB, ZNS
4.6 2 11 LEV, ESM
5.8 12 6 0
9.9 8 10 FELB, STM
13.8 4 7 PGB, VPA, CBL, TPM
1.1 8 3 LEV
10 8 5 TPM, CBZ
7.8 2 9 LEV, ZNS, CLB
4.1 7 8 LEV, PGB
4.7 2 5 OXC, CLB, TPM
6.6 5 5 0
7.4 4 6 LEV, VPA
2.7 4 9 0
9.8 2 5 TPM, LEV
15.3 22 10 LEV
spike and waves during slow sleep. G: generalised epilepsy; GEFS+: generalised
n; MAE: myoclonic astatic epilepsy; MCD: malformation of cortical development;
ars.
Table 2
Modiﬁed Atkins diet protocol at the Danish Epilepsy Centre.
I – At enrolment
 Doctor consultation: considerations about diet treatment, pros and cons,
diet type
 Nurse consultation – further information
 Blood samples: haematology, lipids, lever, electrolytes, Ca, Mg, P,
selenium, metabolic screening, carnitine proﬁle
II – At start of the diet
Prior to start:
 Two hour consultation with nurse & dietician: parent education on
the diet
Recommendations:
 Carbohydrates restricted to 10g/day for the ﬁrst 3 months (both
children and adults), thereafter 15-20g/day if good seizure control
 Fat intake free, but high intake necessary and encouraged:
Recommended vegetable fat rather than animal fat, whenever possible
 Protein intake free, moderate intake suggested
 Carbohydrate conversion table provided:
U 100g ingredient/xg carbohydrate = y gram ingredient (equals 1g
carbohydrate intake)
 Carbohydrate list provided; uses only if no description of contents
in the foods
 Unrestricted mealtimes
 No calorie restriction
 No liquid restriction (use of light soft drinks allowed)
 Supplement of a low-carbohydrate multivitamin and calcium daily
 Booklet of a few calculated recipes provided
 List of suggestions for uncalculated recipes provided
 Weekly-report leaﬂets provided
III – After initiation of the diet: during the ﬁrst 3 months and after 3, 6, 9
and 12 months
Controls:
 Urine ketones twice weekly
 Blood ketones and blood glucose 3 times daily for 2 days for the ﬁrst
4 weeks and later if needed.
 3-days-food-diary after 2 and 8 weeks, to be evaluated by the
dietician for optimizing the diet
 Telephone consultation with the nurse after 5 and 10 weeks for
support
 Outpatient clinic consultation with doctor after 3, 6, 9 and 12 months
 Blood samples after 3, 6, 9 and 12 months
Table 3
Seizure reduction in children actively receiving the MAD at each time point.
Time MAD 3 months
(n=33)
6 months
(n=33)
12 months
(n=17)
>50% seizure reduction* 17 (52%) 13 (39%) 9 (27%)
50–90% seizure reduction 3 (9%) 7 (21%) 5 (15%)
>90% seizure reduction 9 (27%) 6 (18%) 4 (12%)
Seizure-free 5 (15%) 0 0
All percentages are calculated from the total of patients (n=33).
* Total ﬁgures in bold.
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issues during this 2-h consultation with the dietician and the
nurse. After that, families go home and start the diet. A gradual
increase in fat intake is recommended (throughout the ﬁrst days)
to avoid side effects. We start with 10 g carbohydrates per day and
otherwise free calories, protein and mealtimes whilst high fat
intake is encouraged. For our own control, as we just were starting
offering MAD, we asked for standard weekly measurements on
blood glucose, blood ketosis and urine ketosis during the ﬁrst 4
weeks. Liberalizing the 10-g carbohydrate (often increasing but a
few times reducing the intake) was allowed after the ﬁrst 3
months, depending on acceptance, tolerance and effect. Families
come to our keto-clinic for clinical control and blood samples,
every 3 months. Families can however contact their keto-team
nurse and dietician at any time if any problem occurs or with any
question about the diet, medicines or any issues related to their
child’s epilepsy. The MAD protocol is summarized in Table 2.
2.3. Global impression of change in quality of life
Every 3 months, parents responded to a simple questionnaire
developed by the authors (not validated), regarding the global
effect of the diet on attention, behaviour and sleep, as (subjective-
ly) experienced by parents/caregivers. Parents answered the
questions during the consultation with a doctor at 3, 6 and 12
months after diet start. We asked the parents 6 questions to which
they could answer: (1) no change from before diet; (2) little/
moderate improvement; (3) deﬁnite improvement. Questions
were on every day life situations: (1) play (could they maintaininterest in playing? Could they play for a longer time?); (2) eating
situation (could they keep sitting at the table while eating? Could
they eat by themselves better than before?); (3) school/homework
– when relevant for the age (concentration and attention on
homework as required for the age); (4) interaction with parents
and siblings (did they show more interest in contact with near
persons/more attention in contact); (5) alertness (more alert,
longer time per day); (6) sleep (more quiet nights, less awaken-
ings) compared with the situation before the diet. Based on these a
global impression of change, as experienced by parents and/or
caregivers (in the case of both there had to be agreement) were
registered and scored (1–3 for each question). Themaximum score
was 18. A score of 15 or more was considered as global
improvement.
2.4. Statistical analysis
The efﬁcacy between MAD and KD groups was compared using
chi-square test. The patients in the MAD group were older than in
the KD group. Therefore multiple regression analysis for categori-
cal and continuous predictors (age, type of diet, efﬁcacy) was done.
3. Results
3.1. Seizure reduction on MAD
Three months after the start of diet, 52% of patients (17/33)
were responders, i.e. had at least 50% seizure reduction. Out of
these 14 (42%) had >90% seizure reduction after 3 months
(including the 5 patients whowere seizure-free). Some responders
lost effect with time and eventually returned to the pre-diet
situation (Table 3). However 17 patients (52%) remained on the
MAD at least 12 months (at evaluation time) and out of these 9
patients (27% of the 33 enrolled patients) had >50% seizure
reduction. Four of these patients (12%) continued having >90%
seizure reduction (were seizure-free in some periods). Details on
seizure reduction are shown in Table 3.
3.2. Global impression of change in quality of life
24/33 (73%) reported deﬁnite improvement (15 or more of the
18 total points), reﬂecting a global improvement in daily life. The
most consistent effects were that parents and caregivers experi-
enced more alert children during the day, and more quiet nights,
i.e. with fewer awakenings.
3.3. Medication
AEDs were not changed in the ﬁrst 2 months in order to
evaluate the effect of the diet. List of medications tried before the
diet and during the ﬁrst 2 months are listed in Table 1. Children
were receiving on the average 2 (0–4) AEDs at the start of the diet.
Overall, no signiﬁcant reductions in medications were performed
during diet treatment despite the effect of MAD. However, 6
children (18%) beneﬁted from medicine reductions (4 were
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medication and additionally 1 child could be reduced in medicine
dose). None of them resulted in increased seizure frequency.
3.4. Ketosis and blood-glucose
Measurements of blood glucose, blood ketosis and urine ketosis
were made regularly in the ﬁrst 4 weeks. All patients achieved
ketosis within the ﬁrst week and regular urine ketosis measure-
ments throughout the treatment revealed ketosis from 8 to
16 mmol/L in >90% of measurements in 26/33 patients. Twenty-
three out of 33 patients completed blood measurements as
described in Table 2 (weekly measurements in the ﬁrst 4 weeks).
Mean blood ketosis was 2.5 mmol/L (0.8–4.4) and blood glucose
was very stable with >90% of completed measurements between
3.5 and 4.8 mmol/L at any time of the day (before breakfast, before
evening meal, before bedtime).
3.5. Tolerance and side effects
Tolerance was excellent, and practically all families coped well
with the MAD. No patients had to stop the diet because of
hyperketosis, vomiting, extreme fatigue or dislike of the foods.
Subtle side effects such as slight fatigue were reported in the ﬁrst
month by 1/3 of the patients. Continuous support of the families
was decisive for maintaining the diet. Only lack or insufﬁcient
effect was the cause of stopping the diet in all but 1 patient. This
child (patient no. 17) had a bone fracture and stopped the diet; the
patient had epilepsy since 1 month of age and had tried 13
medications during 9 years; however, the child experienced >50%
seizure reduction on the diet.
3.6. Serum lipid proﬁle
Measurements of free cholesterol, triglycerides, cholesterol-
LDL and cholesterol-HDL, in theMAD-group revealed no signiﬁcant
increases above the laboratory references in these parameters in
31/33 children. Only in 2 patients was cholesterolmeasured higher
than 8 mmol/L (upper limit in our lab) on one occasion,
subsequently falling below 8 mmol/L in the next measurement.Table 4
Analysis comparing 33 MAD and 50 KD patients. Seizure-reduction data are at 6 mont
Demographic and clinical data
Male/female
Age: mean (SD)
Seizure frequency before the start of diet: mean (SD)
Symptomatic/cryptogenic, localization-related epilepsies
Idiopathic focal epilepsies
Idiopathic generalised epilepsies
Seizure-reduction (all patients)
<50%
>50%
50–90%
>90%
Seizure-reduction (age-matched MAD: mean age=6.1; n=23; vs. KD; p=0.1)
<50%
>50%
50–90%
>90%
Side-effects
Nausea/vomiting
Hyperketosis (ﬁrst week)
Fatigue (prolonged beyond the ﬁrst week)
Constipation treatment needed (preventive)
No signiﬁcant side effects described beyond the ﬁrst week
Lipids
Increased total cholesterol (1 month after initiation of the diet or later) (>8mmol/
Increased triglycerides (like above) (>2.5mmol/L)Cholesterol results mean on measurements while on the diet were
found to be 4.5 mmol/L (9.8–3.1). Triglycerides mean was found to
be 0.8 mmol/L (2.1–0.3).
In the KD-group, one child had cholesterol higher than 8 mmol/
L on one occasion (1 month after initiation of the diet). Three
children had elevated triglycerides sporadically (1 or 2 occasions)
and only 1 patient had elevated triglycerides in several measure-
ments after 1 month of initiation of the diet.
3.7. Comparison with KD (MAD vs. KD)
Data from these 33 consecutive patients treatedwithMADwere
compared with 50 consecutive patients previously treated by KD in
our Institution (Table 4). KD patients had participated in a previous
study.21 The time point for comparisonwas 6months after the start
of the diet. Responders were deﬁned as those who had more than
50% seizure-reduction at 6 months after the start of the diet.
We did not ﬁnd any statistically signiﬁcant difference between
the responder-rates in the 2 groups, although there was a strong
trend for higher incidence of responders in the KD group (MAD 39%
vs. KD 60%, p = 0.06).
The age of the patients in the MADwas signiﬁcantly higher than
in the KD group. To assess if our results could be biased by this
difference,weperformed twoadditional analyses. Firstwedida sub-
group analysis where in the MAD group we excluded the patients
older than 10 years. The age of this subgroup (<10-years-old) was
not different from the KD group.When this analysis was performed,
there was not even a trend towards signiﬁcance in results (Table 4).
Subsequently, when both types of diet (KD vs. MAD) and age were
included into the multiple regression analysis for categorical and
continuous predictors, their effect became non-signiﬁcant (type of
diet: beta = 0.16, p = 0.18; age: beta = 0.15, p = 0.19).
4. Discussion
Our data suggest that MAD is a highly well tolerated diet in a
mixed group of difﬁcult-to-treat epilepsy children. More than half
of the children had a higher than 50% seizure reduction after 3
months, and more than 1/4 of the patients had more than 90%
seizure reduction after 3 months, which is comparable to mosths after start of diet.
MAD KD p
18/15 27/23 0.9
8.25 (0.7) 4.6 (0.4) <0.001
124 (51) 80 (15) 0.4
31 (94%) 44 (88%) 0.4
1 (3%) 3 (6%) 0.5
1 (3%) 3 (6%) 0.5
20 (61%) 20 (40%) 0.06
13 (39%) 30 (60%)
7 (21%) 13 (26%) 0.62
6 (18%) 17 (34%) 0.11
13 (56%) 20 (40%) 0.19
10 (43%) 30 (60%)
5 (22%) 13 (26%) 0.69
5 (21%) 17 (34%) 0.29
1 (3%) 5 (10%) 0.23
1 (3%) 2 (4%) 0.82
7 (21%) 8 (16%) 0.55
33 (100%) 50 (100%) 1
25 (75%) 39 (78%) 0.81
L) 2 (6%) 1 (2%) 0.33
0 (0%) 3 (6%) 0.15
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(27%) onMAD had been responders, including the 4 children (12%)
with>90% seizure reduction and periods of seizure freedom. These
results are also comparable to most KD studies.8,22
Furthermore, at 6 months after start of diet the results of MAD
were similar to the KD, though therewas trend for higher incidence
of responders in the KD group (39% vs. 60%). However, the patients
in the KD groupwere signiﬁcantly younger than the patients in the
MAD group. This likely reﬂects the higher use of the KD in younger
patients, many of whomwere formula-fed (infants or gastrostomy
tube fed) only.Whenwe adjusted the 2 groups for the difference in
age, the trend disappeared. The young children have been
previously reported in the literature as having higher levels of
seizure reduction and compliance.23,24We feel that for older, solid-
food eating children the results are largely similar and either diet is
therefore acceptable.
Similarly to KD and to AEDs, some patients lose the initial effect
in spite of good compliance, while another group (12%) maintains
the good effect over time. Studies targeting the identiﬁcation of
different patient categories may have future implications for
choosing appropriate diet-candidates, both for KD and MAD.
We ﬁnd it remarkable in this study that a supportive group of
healthcare professionals is needed for achieving the high compli-
ance and good effect in this liberal type of diet, where families are
very much ‘‘on their own’’ compared to the strict dietician control
required for the KD. Networking between families is important too.
In a few children (ex. patients 7, 27, 30), dietician support for
keeping a high fat intake and ketosis was crucial for achieving
seizure freedom/>90% seizure reduction. Parents of those 3
children (patients 7, 27, 30) reported seizure-freedom related to
the amount of fat intake and the level of ketosis. Each of these
families had found the most suitable level for their child. We have
thus practiced the concept of ‘‘patient-tailored diet’’ with success.
We have experienced that in the group with >90% seizure
reduction over time, this was the best approach. Some of these
children have now been on the diet for nearly 2 years where
compliance is still very high combined with very much freedom in
every-day life as reported by these parents. The most striking case
is patient number 7, who by the time of MAD start had epilepsy
with few GTCs and subsequently frequent myoclonic absences
(numerous seizures every day), over almost 10 years, regardless of
AEDs. The parents found the precise amount of fat and ketosis level
onwhich their childwas completely seizure-free, not depending so
much on the precise amount of carbohydrates. The amount of fat
intake seems to be important for some children.
The main message of our study is that a more liberal, less
restrictive and more palatable type of diet, in the setting of a
dedicated team, yields high compliance and similar effectiveness as
a classical, more restrictive KD. This may have important implica-
tions as many more children might beneﬁt from diet treatment
earlier in the course of their epilepsies, avoiding long lasting and
often ineffective medicine trials. As the MAD is less restrictive than
the KD, it may present a more attractive option to families and
neurologists previously reluctant to use dietary treatments.
To the best of our knowledge, this is one of the ﬁrst studies
comparing the effectiveness of a classical and a modiﬁed Atkins
type of diet. We acknowledge the limitations of this study;
especially as the KD experience was retrospective and there was a
bias towards older children starting the MAD. A randomised trial
prospectively comparing both types of diets on similar patients
would be highly informative. However, this might be a very
difﬁcult task as it is well recognised that even patients with
comparable diagnoses may respond differently to the KD and now
after almost 10 years of use of the MAD many parents have strong
personal opinions about which diet they wish their child to start.
Only understanding the variety of mechanisms of action ofketogenic diets in different epilepsy types will eventually lead
to the accurate choice of treatment. It would also be useful to
understandwhich children respond better to the KD, and therefore
switched to that when/if the MAD is unsuccessful.
In conclusion, we found that MAD, a less restrictive type of
ketogenic diet, is a very well-tolerated diet, with high compliance
and very few side effects. Furthermore, MAD was similarly
effective as the classical KD in reducing seizure frequency in
children with medically resistant epilepsy. Continued use of this
alternative diet appears warranted.
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